TLSIW
TriSalus Life Sciences, Inc.
Price Chart
Latest Quote
$0.65
+0.00 (+0.00%)
Current Price
| Previous Close | $0.65 |
| Open | $1.11 |
| Day High | $0.65 |
| Day Low | $0.65 |
| Volume | 109 |
Stock Information
| Total Debt | $34.49M |
| Cash Equivalents | $56.55M |
| Revenue | $44.88M |
| Net Income | $-57.06M |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Sales | $44.88M |
| Income | $-57.06M |
| Book/sh | $0.21 |
| Employees | 102 |
Financial Ratios
| Quick Ratio | 5.24 |
| Current Ratio | 5.78 |
| Debt/Eq | 269.28 |
Returns & Margins
| ROA | -35.17% |
| Gross Margin | 85.07% |
| Operating Margin | -94.52% |
| Profit Margin | -60.85% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | 3.11 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.66 |
| SMA50 | $0.80 |
| SMA200 | $1.23 |
| RSI | 44.60 |
| ATR | 0.0781 |
| Shares Float | 49.29M |
| Volatility | 0.49 |
| Rel Volume | 0.58 |
Performance History
| Week | +25.00% |
| Month | -4.55% |
| Quarter | -56.08% |
| 6 Months | -54.23% |
| YTD | -47.07% |
| Year | -50.00% |
| 3 Years | +828.57% |
| 5 Years | -36.89% |
| 10 Years | -77.64% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $0.65 | 3,000 |
| 2026-06-16 | $0.65 | 2,800 |
| 2026-06-15 | $0.64 | 54,200 |
| 2026-06-12 | $0.75 | 0 |
| 2026-06-11 | $0.75 | 1,000 |
| 2026-06-10 | $0.52 | 0 |
| 2026-06-09 | $0.52 | 0 |
| 2026-06-08 | $0.52 | 3,300 |
| 2026-06-05 | $0.61 | 0 |
| 2026-06-04 | $0.61 | 0 |
| 2026-06-03 | $0.61 | 5,100 |
| 2026-06-02 | $0.56 | 19,300 |
| 2026-06-01 | $0.67 | 0 |
| 2026-05-29 | $0.67 | 500 |
| 2026-05-28 | $0.72 | 100 |
| 2026-05-27 | $0.78 | 3,000 |
| 2026-05-26 | $0.74 | 0 |
| 2026-05-22 | $0.74 | 3,800 |
| 2026-05-21 | $0.85 | 1,300 |
| 2026-05-20 | $0.64 | 6,400 |
| 2026-05-19 | $0.58 | 7,200 |
| 2026-05-18 | $0.68 | 17,800 |
About TriSalus Life Sciences, Inc.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.
đ° Latest News
TriSalus Life Sciences Inc (TLSI) Q1 2026 Earnings Call Highlights: Strategic Expansion and ...
GuruFocus.com âĸ 2026-05-13T05:01:26ZTriSalus Life Sciences Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-13T02:06:19Z
TriSalus Life Sciences, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-13T00:47:35Z
TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-12T21:15:02Z
TriSalus (TLSI) Initiates Patient Enrollment for PREDICTT Liver Tumor Clinical Trial
Insider Monkey âĸ 2026-05-10T04:01:17Z
TriSalus Life Sciences Inc (TLSI) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ...
GuruFocus.com âĸ 2025-11-14T05:04:03ZTriSalus (TLSI) Q3 2025 Earnings Call Transcript
Motley Fool âĸ 2025-11-13T22:34:21Z
TriSalus Life Sciences, Inc. (TLSI) Reports Q3 Loss, Tops Revenue Estimates
Zacks âĸ 2025-11-13T22:15:03Z
TriSalus Life Sciences Inc (TLSI) Q2 2025 Earnings Call Highlights: Strong Sales Growth and ...
GuruFocus.com âĸ 2025-08-13T07:12:42ZTriSalus Life Sciences, Inc. (TLSI) Reports Q2 Loss, Tops Revenue Estimates
Zacks âĸ 2025-08-12T21:10:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $6,965,000 | $4,103,000 | $2,605,000 | $2,258,000 |
| Cost Of Revenue | $6,965,000 | $4,103,000 | $2,605,000 | $2,258,000 |
| Total Revenue | $45,151,000 | $29,431,000 | $18,511,000 | $12,398,000 |
| Operating Revenue | $45,151,000 | $29,431,000 | $18,511,000 | $12,398,000 |
| Expenses | ||||
| Interest Expense | $5,544,000 | $3,090,000 | $16,000 | $1,000 |
| Total Expenses | $72,097,000 | $65,596,000 | $72,986,000 | $48,837,000 |
| Other Income Expense | $-7,285,000 | $8,812,000 | $-5,294,000 | $-10,918,000 |
| Other Non Operating Income Expenses | $-456,000 | $-312,000 | $-6,252,000 | $-8,732,000 |
| Net Non Operating Interest Income Expense | $-4,989,000 | $-2,686,000 | $415,000 | $179,000 |
| Interest Expense Non Operating | $5,544,000 | $3,090,000 | $16,000 | $1,000 |
| Operating Expense | $65,132,000 | $61,493,000 | $70,381,000 | $46,579,000 |
| Selling And Marketing Expense | $28,709,000 | $25,839,000 | $17,034,000 | $12,738,000 |
| General And Administrative Expense | $21,458,000 | $17,966,000 | $23,512,000 | $12,483,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-39,227,000 | $-30,045,000 | $-59,363,000 | $-47,187,000 |
| Net Interest Income | $-4,989,000 | $-2,686,000 | $415,000 | $179,000 |
| Interest Income | $555,000 | $404,000 | $431,000 | $180,000 |
| Normalized Income | $-32,398,000 | $-39,169,000 | $-60,321,000 | $-45,460,060 |
| Net Income From Continuing And Discontinued Operation | $-39,227,000 | $-30,045,000 | $-59,363,000 | $-47,187,000 |
| Total Operating Income As Reported | $-26,946,000 | $-36,165,000 | $-54,475,000 | $-36,439,000 |
| Net Income Common Stockholders | $-69,690,000 | $-33,233,000 | $-63,602,000 | $-50,016,000 |
| Net Income | $-39,227,000 | $-30,045,000 | $-59,363,000 | $-47,187,000 |
| Net Income Including Noncontrolling Interests | $-39,227,000 | $-30,045,000 | $-59,363,000 | $-47,187,000 |
| Net Income Continuous Operations | $-39,227,000 | $-30,045,000 | $-59,363,000 | $-47,187,000 |
| Pretax Income | $-39,220,000 | $-30,039,000 | $-59,354,000 | $-47,178,000 |
| Special Income Charges | $-2,743,000 | $11,231,000 | $11,813,000 | $0 |
| Interest Income Non Operating | $555,000 | $404,000 | $431,000 | $180,000 |
| Operating Income | $-26,946,000 | $-36,165,000 | $-54,475,000 | $-36,439,000 |
| Gross Profit | $38,186,000 | $25,328,000 | $15,906,000 | $10,140,000 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $-459,060 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-26,221,000 | $-35,329,000 | $-59,612,000 | $-44,593,000 |
| Total Unusual Items | $-6,829,000 | $9,124,000 | $958,000 | $-2,186,000 |
| Total Unusual Items Excluding Goodwill | $-6,829,000 | $9,124,000 | $958,000 | $-2,186,000 |
| Reconciled Depreciation | $626,000 | $744,000 | $684,000 | $398,000 |
| EBITDA (Bullshit earnings) | $-33,050,000 | $-26,205,000 | $-58,654,000 | $-46,779,000 |
| EBIT | $-33,676,000 | $-26,949,000 | $-59,338,000 | $-47,177,000 |
| Diluted NI Availto Com Stockholders | $-69,690,000 | $-33,233,000 | $-63,602,000 | $-50,016,000 |
| Otherunder Preferred Stock Dividend | $30,463,000 | $0 | $2,981,000 | $2,829,000 |
| Tax Provision | $7,000 | $6,000 | $9,000 | $9,000 |
| Restructuring And Mergern Acquisition | $2,743,000 | $-11,231,000 | $-10,293,000 | $0 |
| Gain On Sale Of Security | $-4,086,000 | $-2,107,000 | $-10,855,000 | $-2,186,000 |
| Research And Development | $14,965,000 | $17,688,000 | $29,835,000 | $21,358,000 |
| Selling General And Administration | $50,167,000 | $43,805,000 | $40,546,000 | $25,221,000 |
| Other Gand A | $21,458,000 | $17,966,000 | $23,512,000 | $12,483,000 |
| Preferred Stock Dividends | - | $3,188,000 | $1,258,000 | $2,829,000 |
| Other Special Charges | - | - | $-1,520,000 | $8,312,000 |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-33,861,000 | $-25,894,000 | $-27,065,000 | $-177,132,000 |
| Total Assets | $35,331,000 | $23,971,000 | $24,598,000 | $21,995,000 |
| Total Non Current Assets | $3,087,000 | $3,302,000 | $3,736,000 | $4,781,000 |
| Other Non Current Assets | $418,000 | $423,000 | $466,000 | $367,000 |
| Current Assets | $32,244,000 | $20,669,000 | $20,862,000 | $17,214,000 |
| Prepaid Assets | $2,170,000 | $3,009,000 | $2,986,000 | $4,772,000 |
| Inventory | $3,077,000 | $4,048,000 | $2,545,000 | $1,471,000 |
| Receivables | $6,558,000 | $5,087,000 | $3,554,000 | $1,557,000 |
| Accounts Receivable | $6,558,000 | $5,087,000 | $3,554,000 | $1,557,000 |
| Cash Cash Equivalents And Short Term Investments | $20,439,000 | $8,525,000 | $11,777,000 | $9,414,000 |
| Cash And Cash Equivalents | $20,439,000 | $8,525,000 | $11,777,000 | $9,414,000 |
| Goodwill And Other Intangible Assets | - | - | $1,127,000 | $802,000 |
| Debt | ||||
| Net Debt | $12,607,000 | $13,559,000 | - | - |
| Total Debt | $34,441,000 | $23,629,000 | $1,595,000 | $1,963,000 |
| Long Term Debt And Capital Lease Obligation | $34,274,000 | $23,413,000 | $1,244,000 | $1,593,000 |
| Long Term Debt | $33,046,000 | $22,084,000 | - | - |
| Current Debt And Capital Lease Obligation | $167,000 | $216,000 | $351,000 | $370,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $69,192,000 | $49,865,000 | $51,663,000 | $198,325,000 |
| Total Non Current Liabilities Net Minority Interest | $57,693,000 | $39,637,000 | $36,976,000 | $165,968,000 |
| Other Non Current Liabilities | $23,419,000 | $16,224,000 | $35,732,000 | $369,000 |
| Current Liabilities | $11,499,000 | $10,228,000 | $14,687,000 | $32,357,000 |
| Other Current Liabilities | $234,000 | $383,000 | $389,000 | $20,663,000 |
| Payables And Accrued Expenses | $8,777,000 | $7,173,000 | $9,884,000 | $8,099,000 |
| Payables | $3,102,000 | $2,308,000 | $3,422,000 | $4,947,000 |
| Total Tax Payable | $100,000 | $34,000 | $31,000 | $0 |
| Accounts Payable | $3,002,000 | $2,274,000 | $3,391,000 | $4,947,000 |
| Derivative Product Liabilities | - | - | - | $369,000 |
| Equity | ||||
| Common Stock Equity | $-33,861,000 | $-25,894,000 | $-27,065,000 | $-176,330,000 |
| Total Equity Gross Minority Interest | $-33,861,000 | $-25,894,000 | $-27,065,000 | $-176,330,000 |
| Stockholders Equity | $-33,861,000 | $-25,894,000 | $-27,065,000 | $-176,330,000 |
| Retained Earnings | $-330,583,000 | $-279,549,000 | $-249,504,000 | $-186,358,000 |
| Preferred Securities Outside Stock Equity | - | - | $0 | $164,006,000 |
| Other | ||||
| Ordinary Shares Number | $49,997,836 | $31,279,264 | $26,413,213 | $26,316,681 |
| Share Issued | $49,997,836 | $31,279,264 | $26,413,213 | $26,316,681 |
| Tangible Book Value | $-33,861,000 | $-25,894,000 | $-27,065,000 | $-177,132,000 |
| Invested Capital | $-815,000 | $-3,810,000 | $-27,065,000 | $-176,330,000 |
| Working Capital | $20,745,000 | $10,441,000 | $6,175,000 | $-15,143,000 |
| Capital Lease Obligations | $1,395,000 | $1,545,000 | $1,595,000 | $1,963,000 |
| Total Capitalization | $-815,000 | $-3,810,000 | $-27,065,000 | $-176,330,000 |
| Additional Paid In Capital | $296,718,000 | $253,652,000 | $222,437,000 | $10,028,000 |
| Capital Stock | $4,000 | $3,000 | $2,000 | $0 |
| Common Stock | $4,000 | $3,000 | $2,000 | $0 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $1,228,000 | $1,329,000 | $1,244,000 | $1,593,000 |
| Current Capital Lease Obligation | $167,000 | $216,000 | $351,000 | $370,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,321,000 | $2,456,000 | $4,063,000 | $3,225,000 |
| Current Accrued Expenses | $5,675,000 | $4,865,000 | $6,462,000 | $3,152,000 |
| Net PPE | $2,669,000 | $2,879,000 | $3,270,000 | $3,612,000 |
| Accumulated Depreciation | $-3,233,000 | $-3,787,000 | $-3,093,000 | $-2,425,000 |
| Gross PPE | $5,902,000 | $6,666,000 | $6,363,000 | $6,037,000 |
| Leases | $1,571,000 | $772,000 | $772,000 | $772,000 |
| Construction In Progress | $248,000 | $331,000 | $598,000 | - |
| Other Properties | $874,000 | $1,223,000 | $1,192,000 | $1,393,000 |
| Machinery Furniture Equipment | $3,209,000 | $4,340,000 | $3,801,000 | $3,872,000 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-109,000 | $-10,000 | $-117,000 | - |
| Finished Goods | $1,897,000 | $2,720,000 | $2,055,000 | $718,000 |
| Raw Materials | $1,289,000 | $1,338,000 | $607,000 | $753,000 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-18,930,000 | $-41,188,000 | $-51,166,000 | $-33,099,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-18,012,000 | $-40,843,000 | $-50,578,000 | $-32,313,000 |
| Cash Flow From Continuing Operating Activities | $-18,012,000 | $-40,843,000 | $-50,578,000 | $-32,313,000 |
| Operating Gains Losses | $4,206,000 | $2,130,000 | $9,379,000 | $2,496,000 |
| Investing Activities | ||||
| Capital Expenditure | $-918,000 | $-345,000 | $-588,000 | $-786,000 |
| Investing Cash Flow | $-838,000 | $-345,000 | $-1,588,000 | $-1,786,000 |
| Cash Flow From Continuing Investing Activities | $-838,000 | $-345,000 | $-1,588,000 | $-1,786,000 |
| Net Other Investing Changes | - | - | $-1,000,000 | $-1,000,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $22,000,000 | $15,104,000 | $9,189,000 | $13,499,000 |
| Financing Cash Flow | $30,764,000 | $37,936,000 | $54,629,000 | $13,462,000 |
| Cash Flow From Continuing Financing Activities | $30,764,000 | $37,936,000 | $54,629,000 | $13,462,000 |
| Net Other Financing Charges | $-2,069,000 | $-2,593,000 | $35,738,000 | - |
| Net Common Stock Issuance | $22,000,000 | $15,104,000 | $0 | - |
| Common Stock Issuance | $22,000,000 | $15,104,000 | $0 | - |
| Net Preferred Stock Issuance | - | $0 | $9,189,000 | $13,499,000 |
| Preferred Stock Issuance | - | $0 | $9,189,000 | $13,499,000 |
| Other | ||||
| Repayment Of Debt | $-81,000 | $-84,000 | $-87,000 | $-131,000 |
| Issuance Of Debt | $10,000,000 | $25,000,000 | $0 | $0 |
| Interest Paid Supplemental Data | $3,697,000 | $1,750,000 | $18,000 | $0 |
| Income Tax Paid Supplemental Data | $16,000 | $18,000 | $14,000 | $9,000 |
| End Cash Position | $20,789,000 | $8,875,000 | $12,127,000 | $9,664,000 |
| Beginning Cash Position | $8,875,000 | $12,127,000 | $9,664,000 | $30,301,000 |
| Changes In Cash | $11,914,000 | $-3,252,000 | $2,463,000 | $-20,637,000 |
| Proceeds From Stock Option Exercised | $914,000 | $509,000 | $9,789,000 | $94,000 |
| Net Issuance Payments Of Debt | $9,919,000 | $24,916,000 | $-87,000 | $-131,000 |
| Net Long Term Debt Issuance | $9,919,000 | $24,916,000 | $-87,000 | $-131,000 |
| Long Term Debt Payments | $-81,000 | $-84,000 | $-87,000 | $-131,000 |
| Long Term Debt Issuance | $10,000,000 | $25,000,000 | $0 | $0 |
| Net PPE Purchase And Sale | $-838,000 | $-345,000 | $-588,000 | $-655,000 |
| Sale Of PPE | $80,000 | $0 | - | - |
| Purchase Of PPE | $-918,000 | $-345,000 | $-588,000 | $-655,000 |
| Change In Working Capital | $2,068,000 | $-9,549,000 | $537,000 | $2,300,000 |
| Change In Other Current Liabilities | $-134,000 | $-278,000 | $-281,000 | $-87,000 |
| Change In Payables And Accrued Expense | $2,020,000 | $-4,384,000 | $2,838,000 | $5,246,000 |
| Change In Prepaid Assets | $845,000 | $-1,665,000 | $1,032,000 | $-2,592,000 |
| Change In Inventory | $971,000 | $-1,503,000 | $-1,073,000 | $-179,000 |
| Change In Receivables | $-1,634,000 | $-1,719,000 | $-1,979,000 | $-200,000 |
| Changes In Account Receivables | $-1,634,000 | $-1,719,000 | $-1,979,000 | $-200,000 |
| Other Non Cash Items | $5,021,000 | $-9,751,000 | $-3,217,000 | $9,312,000 |
| Stock Based Compensation | $9,131,000 | $5,441,000 | $1,402,000 | $368,000 |
| Provisionand Write Offof Assets | $163,000 | $187,000 | $0 | - |
| Depreciation Amortization Depletion | $626,000 | $744,000 | $684,000 | $398,000 |
| Depreciation And Amortization | $626,000 | $744,000 | $684,000 | $398,000 |
| Depreciation | $626,000 | $744,000 | $684,000 | $276,000 |
| Gain Loss On Investment Securities | $4,086,000 | $2,107,000 | $10,855,000 | $2,186,000 |
| Gain Loss On Sale Of PPE | $120,000 | $23,000 | $44,000 | $310,000 |
| Net Income From Continuing Operations | $-39,227,000 | $-30,045,000 | $-59,363,000 | $-47,187,000 |
| Change In Payable | - | $-4,384,000 | $2,838,000 | $5,246,000 |
| Change In Account Payable | - | $-4,384,000 | $2,838,000 | $5,246,000 |
| Net Intangibles Purchase And Sale | - | - | $-533,000 | $-131,000 |
| Purchase Of Intangibles | - | - | $-533,000 | $-131,000 |
| Change In Other Current Assets | - | - | $202,000 | $112,000 |
| Asset Impairment Charge | - | - | $190,000 | $0 |
| Amortization Cash Flow | - | - | $18,000 | $122,000 |
| Amortization Of Intangibles | - | - | $18,000 | $122,000 |
Fetched: 2026-06-16